Arcturus Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage mRNA medicines company, announced its participation in several upcoming investor conferences. Notable events include:

• BIO CEO & Investor Digital Conference: February 12, 2021, at 12:00 p.m. ET
• Raymond James Annual Institutional Investors Conference: March 3, 2021, at 11:40 a.m. ET
• H.C. Wainwright Global Life Sciences Conference: March 9, 2021, at 7:00 a.m. ET
• Barclays Global Healthcare Conference: March 10, 2021, at 1:50 p.m. ET

Arcturus focuses on developing vaccines and treatments for infectious diseases.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor conferences.

BIO CEO & Investor Digital Conference

• Presentation
• Date: Friday, February 12, 2021
• Time: 12:00 p.m. ET

Raymond James 42^nd Annual Institutional Investors Conference

• Fireside Chat
• Date: Wednesday, March 3, 2021
• Time: 11:40 a.m. ET

H.C. Wainwright Global Life Sciences Conference

• Fireside Chat
• Date: Tuesday, March 9, 2021
• Time: 7:00 a.m. ET

Barclays Global Healthcare Conference

• Fireside Chat
• Date: Wednesday, March 10, 2021
• Time: 1:50 p.m. ET

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, and Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (205 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005356/en/

FAQ

What conferences is Arcturus Therapeutics participating in February and March 2021?

Arcturus Therapeutics will participate in the BIO CEO & Investor Digital Conference on February 12, Raymond James Annual Institutional Investors Conference on March 3, H.C. Wainwright Global Life Sciences Conference on March 9, and Barclays Global Healthcare Conference on March 10, 2021.

What is the date and time for Arcturus Therapeutics' presentation at the BIO CEO & Investor Digital Conference?

The presentation for Arcturus Therapeutics at the BIO CEO & Investor Digital Conference is scheduled for February 12, 2021, at 12:00 p.m. ET.

When is Arcturus Therapeutics' fireside chat at the Raymond James Conference?

The fireside chat for Arcturus Therapeutics at the Raymond James Annual Institutional Investors Conference will take place on March 3, 2021, at 11:40 a.m. ET.

What is the focus of Arcturus Therapeutics' mRNA medicines?

Arcturus Therapeutics focuses on the development of vaccines and treatments for infectious diseases, as well as liver and respiratory rare diseases.

What technologies does Arcturus Therapeutics employ in its drug development?

Arcturus Therapeutics utilizes LUNAR® lipid-mediated delivery technology, STARR™ mRNA Technology, and has expertise in mRNA drug substance along with drug product manufacturing.